Sartorius Stedim Biotech SA
/ Key word(s): Expansion
Aubagne, France | June 17, 2025 Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France
"By investing in innovation, automation, and sustainability, we are strengthening our ability to meet the evolving needs of our customers while ensuring our competitive positioning and preparing for future growth. This emphasizes our commitment to simplify and accelerate progress in bioprocessing with advanced technologies, enabling new and better therapies to be manufactured faster, more efficiently and more sustainably," said René Fáber, CEO of Sartorius Stedim Biotech. To meet the growing demand for single-use bioprocessing solutions, Sartorius Stedim Biotech almost doubled cleanroom space to around 9,000 square meters. Automated and digitized production lines for 2D and 3D single-use bags increase productivity and reliability. Certified with ISCC Plus1, the site uses renewable raw materials to produce plastic components, significantly reducing the share of fossil-based materials in products. The company also adopted ISO 14001, a standard for environmental management systems, to improve the environmental performance and reduce the ecological footprint of its operations. An automated logistics facility accelerates raw material handling for single-use bag manufacturing. The new 12,000-square-meter high-bay warehouse is optimized for efficient processing of pallets. Autonomous forklifts and mobile robots streamline operations utilizing a Goods-To-Person approach, enabling operators to focus on specialized work. The facility will be fully operational by fall 2025. The expanded site also includes a new 1,900-square-meter cross-functional lab space, designed to extend collaboration between internal teams and external partners. The facility houses product development labs for fluid management and cell culture technologies, as well as application labs for customer demos and training. It opened its doors to customers in early 2024. A modern office building at the center of the campus, including a showroom and a conference center, as well as amenities such as a restaurant and a gym, complement the new facilities. The total area of the premises has quadrupled to around 90,000 square meters since 2020. Designed to meet high environmental standards and minimize the ecological footprint of the facility, the buildings earned HQE® Excellent and BiodiverCity® certifications for sustainable construction and biodiversity measures. Since 2021, Sartorius Stedim Biotech has invested significantly in its French operations, including Lourdes, Cergy, Pompey, and Strasbourg. Today, around 1,400 employees work at seven sites in France-thereof more than 1,100 in Aubagne. Over the past ten years, the number of employees in the country has approximately doubled. 1 International Sustainability and Carbon Certification PLUS (ISCC PLUS) Further information Find images of Sartorius Stedim Biotech Aubagne here A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Contacts Petra Kirchhoff Head of Corporate Communications & IR +49 551 308 1686 petra.kirchhoff@sartorius.com Attachment File: Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France | Media Release Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2155962 |
| End of Announcement - EQS News Service | |
2155962 17-Jun-2025 CET/CEST
© 2025 EQS Group
